{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257558","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2026-06-04T20:37:03+00:00","discovered_at":"2026-06-04T20:38:00.425047+00:00","generated_at":"2026-06-04T21:08:12.304490+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"low","headline":"Fate updates corporate presentation for EULAR 2026; no specific new data in exhibit","bullets":["Company filed an updated corporate presentation for use at the EULAR 2026 Congress on June 4, 2026.","Presentation focuses on cell therapies for autoimmune diseases and cancer; ticker FATE listed on Nasdaq.","No financial results, pipeline updates, or concrete milestones disclosed in the excerpted exhibit.","Event is a routine update of investor materials; materiality is limited given lack of specific numbers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257558","json":"https://secwatch.observer/filing/0001193125-26-257558.json","markdown":"https://secwatch.observer/filing/0001193125-26-257558.md","text":"https://secwatch.observer/filing/0001193125-26-257558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526257558/0001193125-26-257558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526257558/d83385d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:08:12.304490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}